Market revenue in 2021 | USD 64.5 million |
Market revenue in 2030 | USD 147.6 million |
Growth rate | 9.6% (CAGR from 2021 to 2030) |
Largest segment | Clinical |
Fastest growing segment | Preclinical |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Preclinical, Clinical |
Key market players worldwide | Labcorp Holdings Inc, IQVIA Holdings Inc, Syneos Health, SGS AG, Toxikon, Intertek Group PLC, Pace Analytical Services, Icon PLC, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule bioanalytical testing services market will help companies and investors design strategic landscapes.
Clinical was the largest segment with a revenue share of 66.05% in 2021. Horizon Databook has segmented the China large molecule bioanalytical testing services market based on preclinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Rising number of clinical trials in the country will drive the market for large molecule bioanalytical testing over the forecast period. For instance, China conducted 46,149 clinical trials between 1999 and 2019, according to WHO’s ICTRP.
This contributes to around 8.8% of total clinical trials conducted globally in the same period. Furthermore, according to the World Bank, the healthcare expenditure of China was 5.4% of its GDP in 2018. Significant healthcare expenditure in the country will drive the large molecule bioanalytical testing market as well.
Favorable government policies, such as the “Made in China 2025,” will also improve funding of biopharmaceutical R&D. Such policies in the country will are expected to drive market growth in China. Moreover, significantly high geriatric population will augment the need for advanced health, driving the large molecule bioanalytical testing market.
Horizon Databook provides a detailed overview of country-level data and insights on the China large molecule bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into China large molecule bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account